AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06369831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-ABSCINT-HER2 PET/CT
Description: 68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
Study NCT06475846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5580
Description: HRS5580; middle dose
Study NCT06475846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron
Study NCT06475846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank preparation
Description: blank preparation.
Study NCT05781087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography and pressure wire assessment
Description: Non-culprit coronary arteries
Study NCT05781087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance angiogram
Description: 1.5T
Study NCT05448742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biplanar PSI slope-reducing MOWHTO.
Description: High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
Study NCT06467344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACDN-01
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Study NCT05230797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc oxide Propolis
Description: antibacterial and anti-inflammatory
Study NCT06334965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous 18F-Choline PET-MRI
Description: before first TARE administration (after work-up procedure) and one month after TARE administration
Study NCT06451159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 (Biological) - 0.33 ×10^8 cells
Description: KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
Study NCT06451159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 (Biological) - 1 ×10^8 cells
Description: KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
Study NCT06451159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: cyclophosphamide (CYC)
Description: Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
Study NCT06451159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: fludarabine (FLU)
Description: Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
Study NCT06262932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
Study NCT06086418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % Sodium Chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Study NCT06086418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Study NCT06086418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
Study NCT04070066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital didactic environment
Description: Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
Study NCT04070066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: • Simulated scenario
Description: The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
Study NCT06333652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Intravenous infusion 100 mg/ml
Study NCT05137080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline
Study NCT05889871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard endocrine therapy plus Apatinib
Description: Standard endocrine therapy plus Apatinib
Study NCT05889871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard endocrine therapy plus Apatinib
Description: Standard endocrine therapy plus Apatinib
Study NCT05092490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined serratus anterior plane block and transversus thoracis plane block
Description: The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
Study NCT05092490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard local infiltration technique
Description: Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
Study NCT05230797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Oxide-Eugenol Cement
Description: Antimicrobial and antiseptic
Study NCT04877418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TeleCIMT
Description: Mode applied remotely, through the principles and components of the CIMT protocol.
Study NCT06415435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Microneedling
Description: Sylfirm X radiofrequency microneedling device
Study NCT06487182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: reiki
Study NCT06487182 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo reiki
Description: placebo reiki
Study NCT06397313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Study NCT06397313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
Study NCT04039204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
Study NCT04039204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Oral contraceptive prescribed by physician.
Study NCT06346782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Parent-Child Interaction Therapy
Description: I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
Study NCT06346782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Parent-Child Interaction Therapy
Description: I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
Study NCT05019573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black tea
Description: Black tea twice a day for 4 weeks
Study NCT05019573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tea twice a day for 4 weeks
Study NCT05764954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T System
Description: The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
Study NCT06553404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoslow
Description: The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
Study NCT06553404 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision
Description: Single vision glasses
Study NCT05795491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Emitting Diode Therapy
Description: Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
Study NCT05320419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane preparation and injection (AM group)
Description: The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
Study NCT05320419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy (PT group)
Description: Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
Study NCT06110598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
Study NCT05820490 — intervention group
Intervention type: OTHER
Intervention: Whole Room Calorimeter
Description: The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.
Study NCT05820490 — intervention group
Intervention type: OTHER
Intervention: Mixed-Meal Tolerance Test (MMTT)
Description: The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.
Study NCT05820490 — intervention group
Intervention type: OTHER
Intervention: Core Body Temperature
Description: Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.
Study NCT05820490 — intervention group
Intervention type: OTHER
Intervention: Morningness-Eveningness Questionnaire
Description: Participants will fill out a questionnaire that asks about your preference for morning or evening.
Study NCT05820490 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.
Study NCT05820490 — intervention group
Intervention type: OTHER
Intervention: Serial Blood Sampling
Description: Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
Study NCT04411758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
Study NCT04411758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
Study NCT04955613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyMove/VR system
Description: The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers.
Study NCT04955613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
Study NCT04744506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Marker Clip
Description: Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
Study NCT04744506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticle Suspension Injection
Description: Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
Study NCT04744506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticle Suspension Injection
Description: Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
Study NCT06593834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacillus coagulans combined with the best treatment options for preventing aGVHD
Description: BAT means the best treatment options for preventing aGVHD
Study NCT06593834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT
Study NCT06609291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology
Description: The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
Study NCT06612216 — intervention group
Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.
Study NCT06611826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
Description: The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
Study NCT06612905 — intervention group
Intervention type: OTHER
Intervention: Detection of the time spent on social media
Description: The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).
Study NCT06612905 — intervention group
Intervention type: OTHER
Intervention: Evaluation of body composition and basal metabolic rate
Description: They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)
Study NCT06612905 — intervention group
Intervention type: OTHER
Intervention: Evaluation of eating behavior among social media users
Description: Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
Study NCT06612983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.
Study NCT06612983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Treatment
Description: Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.
Study NCT01514942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Myo-inositol + Folic acid
Description: Myo-inositol (2g) Folic acid (200mcg) (2 per day)
Study NCT01514942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-chiro-inositol, manganese, folic acid, vit B12
Description: D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
Study NCT01514942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-chiro-inositol, manganese, folic acid, vit B12
Description: D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)